Nobivac Respira Bb

10 x 1 dose

Suspension for injection

Active substance

Bordetella bronchiseptica (fimbriae), (strain Bb7 92937)

ATC code

QI07AB03 Bordetella

QI07AB Inactivated bacterial vaccines (including Mycoplasma, Toxoid and Chlamydia)

QI07A Immunologicals for dog

QI07 Immunologicals for canidae

QI Immunologicals

Species

Dogs.

Indications

For active immunisation of dogs against Bordetella bronchiseptica to reduce clinical signs of upper respiratory tract disease and bacterial shedding post infection.

Onset of immunity:

2 weeks.

Duration of immunity:

7 months after primary vaccination.

1 year after revaccination.

Dose to be administered and administration route

Subcutaneous use, 1 ml dose per vaccination.

Dogs can be vaccinated from the age of 6 weeks onwards.

Allow the vaccine to reach room temperature (15 °C – 25 °C) before use.

Shake well before each administered dose. Avoid introduction of contamination by using a clean needle for each administered dose.

Primary vaccination:

Two vaccinations with an interval of 4 weeks.

Revaccination:

A single vaccination, administered 7 months after primary vaccination with this vaccine, is sufficient to maintain protection against Bordetella bronchiseptica for a further year. Thereafter, a single vaccination should be administered, annually. In case revaccination at 7 months is missed, a single vaccination within 12 months after primary vaccination is sufficient to extend protection against Bordetella bronchiseptica for a further year.

This vaccine can also be used for revaccination in a schedule where Nobivac KC has been used for primary vaccination. A single vaccination, administered one year after primary vaccination with Nobivac KC, is sufficient to prolong immunity against Bordetella bronchiseptica for another year.

Revaccination after primary vaccination with Nobivac KC:

One vaccination, annually.

For associated use:

When this vaccine is administered in associated use (i.e. not mixed) with another vaccine in the Nobivac range as indicated under section 4.8, the vaccines should be given subcutaneously at the same time, at a different site. Dogs should not be younger than the minimum age recommended for the other Nobivac vaccine, as stated in the respective product information.

Adverse reactions

Dogs:

Very common

(> 1 animal / 10 animals treated):

Injection site swelling (≤ 2 cm, occasionally firm, may be present up to 25 days post-vaccination).

Common

(1 to 10 animals / 100 animals treated):

Injection site swelling (≤ 3.5 cm may be present up to 25 days post-vaccination¹ and can be painful).

Very rare

(< 1 animal / 10,000 animals treated, including isolated reports):

Hypersensitivity reaction.²

¹ The swelling may uncommonly last for up to 35 days post-vaccination.

² If hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.